Know Cancer

or
forgot password

Phase II Study of Oxaliplatin in Combination With Navelbine for the Second-Line Treatment of Advanced and Metastatic Non-Small Cell Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Previously Treated Metastatic Non-Small Cell Lung Cancer

Thank you

Trial Information

Phase II Study of Oxaliplatin in Combination With Navelbine for the Second-Line Treatment of Advanced and Metastatic Non-Small Cell Lung Cancer


This is a non-randomized trial for patients with previously treated Non-small cell lung
cancer. Each patient will receive 6 cycles of chemotherapy consisting of Oxaliplatin and
Navelbine. Oxaliplatin is given intravenously every 21 days and Navelbine is administered
Intravenously on day 1 and day 8 every 21 days.


Inclusion Criteria:



- Locally advanced or metastatic non-small cell lung cancer that has recurred,
progressed, or failed to respond to previous systemic chemo.

- Measurable disease

- Good performance status (ECOG 0,1 or 2)

Exclusion Criteria:

- Previously treated with Oxaliplatin or Navelbine

- Symptomatic CNS metastases

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy

Principal Investigator

Thomas A Marsland, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Integrated Community Oncology Network

Authority:

United States: Institutional Review Board

Study ID:

OX-03-087

NCT ID:

NCT00238849

Start Date:

Completion Date:

Related Keywords:

  • Previously Treated Metastatic Non-Small Cell Lung Cancer
  • Non-small cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Integrated Community Oncology NetworkJacksonville Beach, Florida  32250